Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy
"More than half of all narcolepsy patients report that their symptoms began as teenagers or in childhood. Although narcolepsy in children is characterized by the same symptoms as adults, pediatric narcolepsy is frequently under-recognized and under-diagnosed," said
About the Global Phase 2/3 EXPRESS1 Study
The EXPRESS study is a double-blind, placebo-controlled, randomized-withdrawal, multicenter study evaluating the efficacy and safety of Xyrem with an open-label pharmacokinetic evaluation and safety extension for at least one year in pediatric patients with narcolepsy with cataplexy. The study enrolled 106 patients aged seven to seventeen with narcolepsy with cataplexy. The study design included a titration period (if necessary), a Xyrem stable-dose period of two to three weeks, followed by a 1:1 randomization to either Xyrem or placebo for 2 weeks. After the completion of the double-blind, placebo-controlled treatment period, patients have the opportunity to receive Xyrem in an open-label treatment phase for at least one year. After a pre-planned interim analysis, efficacy on the primary endpoint was demonstrated. As a result, randomization to placebo was discontinued, and the study remains ongoing with open-label Xyrem treatment.
The primary efficacy endpoint was the change in the weekly number of cataplexy attacks from the last 2 weeks of the stable-dose period to the 2 weeks of the double-blind placebo-controlled treatment period. The key secondary endpoints measured the CGIc for cataplexy severity and the ESS (
About Narcolepsy
Narcolepsy is a debilitating neurological disorder characterized by excessive sleepiness, and the inability to regulate sleep-wake cycles normally. It affects an estimated one in 2,000 people in
About
About Xyrem
Xyrem oral solution, CIII, is indicated for the treatment of cataplexy in narcolepsy and for the treatment of excessive daytime sleepiness (
IMPORTANT SAFETY INFORMATION
Xyrem is a central nervous system (CNS) depressant. In clinical trials at recommended doses obtundation and clinically significant respiratory depression occurred in Xyrem-treated patients. Almost all of the patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants.
Xyrem is the sodium salt of gamma hydroxybutyrate (GHB). Abuse of GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.
Because of the risks of CNS depression, abuse, and misuse, Xyrem is available only through a restricted distribution program called the Xyrem REMS Program, using the central pharmacy that is specially certified. Prescribers and patients must enroll in the program. For further information go to www.XYREMREMS.com or call 1-866-XYREM88® (1-866- 997-3688).
Xyrem is contraindicated in combination with sedative hypnotics or alcohol and in patients with succinic semialdehyde dehydrogenase deficiency.
Caution should be used when considering the concurrent use of Xyrem with other CNS depressants. Healthcare providers should caution patients against hazardous activities requiring complete mental alertness or motor coordination within the first 6 hours of dosing or after first initiating treatment until certain that Xyrem does not affect them adversely. The rapid onset of sedation, coupled with the amnestic features of Xyrem, particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (e.g. assault victim). Patients should be monitored for emergent or increased depression and suicidality and for impaired motor/cognitive function. Episodes of sleepwalking should be fully evaluated and appropriate interventions considered. The amount of daily sodium intake in each dose of Xyrem should be considered in patients sensitive to salt intake. The most common adverse reactions were nausea, dizziness, vomiting, somnolence, enuresis, and tremor.
Please click here to see the full Prescribing Information for Xyrem, including BOXED Warning.
Reference:
1 EXPRESS stands for the Effect of Xyrem in Pediatric naRcolEpSy patientS
2 Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A, Billiard M. Age at onset of narcolepsy in two large populations of patients in
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to the expected presentation of results from the company's Phase 2/3 pediatric narcolepsy study evaluating narcolepsy with cataplexy, the company's plans for submission of a supplemental NDA with the
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-positive-results-from-the-phase-23-express-study-of-xyrem-in-pediatric-patients-with-narcolepsy-with-cataplexy-300444496.html
SOURCE
Jazz Pharmaceuticals Contacts: Investors: Kathee Littrell, Vice President, Investor Relations, Ireland, +353 1 634 7887, U.S., +1 650 496 2717; Media: Jacqueline Kirby, Vice President, Corporate Affairs & Government Relations, Ireland, +353 1 697 2141, U.S., +1 215 867 4910